SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Angiology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Heiss, H.W.
Right arrow Articles by Deichsel, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heiss, H.W.
Right arrow Articles by Deichsel, G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reocclusion Prophylaxis with Dipyridamole Combined with Acetylsalicylic Acid Following PTA

H.W. Heiss, M.D., F.I.C.A.

Department of Internal Medicine , Medical Clinic, University of Freiburg

H. Just, M.D.

Department of Internal Medicine , Medical Clinic, University of Freiburg

D. Middleton, M.D.

Dr. Karl Thomae GmbH, Biberach, West Germany

G. Deichsel, M.D.

Dr. Karl Thomae GmbH, Biberach, West Germany

After primary successful PTA, 199 patients were randomized into one of three treatment groups, namely, placebo or a combination of 75 mg dipyridamole with either 330 mg (high dose) or 100 mg (low dose) acetylsalicylic acid (ASA) tid. The duration of treatment was six months. Of the 199 patients admitted to the study, 156 completed the six-month trial period. Not all patients had a second angiogram, and in these cases clinical findings were used in the evaluation.

Evaluation of the combined angiographic and clinical results showed improvement or no deterioration in 37% of patients in the placebo group compared with 49% in the low-dose and 61% in the high-dose ASA groups respectively. The only statistically significant difference observed was between the placebo group and the group treated with dipyridamole and high-dose ASA (p = 0.01). This difference remained statistically significant at p = 0.039 if only the angiographic findings were considered for group comparison. It cannot, however, be concluded from this study that 75 mg dipyridamole in combination with 100 mg ASA tid is more effective in preventing reocclusion after PTA than in combination with 330 mg ASA tid.

Angiology, Vol. 41, No. 4, 263-269 (1990)
DOI: 10.1177/000331979004100402


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
JAMAHome page
J. S. Berger, M. J. Krantz, J. M. Kittelson, and W. R. Hiatt
Aspirin for the Prevention of Cardiovascular Events in Patients With Peripheral Artery Disease: A Meta-analysis of Randomized Trials
JAMA, May 13, 2009; 301(18): 1909 - 1919.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
M. Sobel and R. Verhaeghe
Antithrombotic Therapy for Peripheral Artery Occlusive Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 815S - 843S.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
G. P. Clagett, M. Sobel, M. R. Jackson, G. Y. H. Lip, M. Tangelder, and R. Verhaeghe
Antithrombotic Therapy in Peripheral Arterial Occlusive Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 609S - 626S.
[Abstract] [Full Text] [PDF]


Home page
PERSPECT VASC SURG ENDOVASC THERHome page
G. Mozes and P. Gloviczki
Adjuvant Therapy in Lower Extremity Revascularization: Prevention of Early and Intermediate Failures
Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 2002; 15(2): 161 - 180.
[Abstract] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
H. K. Breddin
Antiplatelet Agents in Cardiovascular and Cerebrovascular Diseases
Clinical and Applied Thrombosis/Hemostasis, April 1, 1998; 4(2): 87 - 95.
[Abstract] [PDF]



Advertisement